Immunotherapy plus anti-angiogenic drugs for advanced liver cancer
Part of Cancer clinical trials.
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (HCC) that cannot be removed with surgery or has spread.
- You have not had any prior whole-body cancer treatment (like chemo or targeted drugs).
- Your cancer is at BCLC stage B or C and you are not a candidate for surgery or local treatments.
- You have at least one measurable tumor on a scan.
- You are in good physical condition (ECOG score 0 or 1) and your liver function is stable (Child-Pugh A5 to B7).
- You do not have certain other serious conditions like uncontrolled bleeding, blood clots, or severe high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (checkpoint inhibitors) and anti-VEGF therapy (which blocks blood vessel growth to tumors) with or without local treatments (like chemoembolization) for advanced liver cancer. It aims to see if the combination works better than current treatments.
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This trial tests a combination of two drugs (Adebrelimab, an immunotherapy, plus Apatinib, a targeted therapy) for people with advanced liver cancer who have already tried other treatments. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two drugs (bevacizumab and adebrelimab) plus a special procedure called TACE-HAIC to treat advanced liver cancer that cannot be surgically removed. The goal is to see if this combination is safe and effective as a first-line treatment.
This trial tests SHR-8068 combined with adebrelimab and bevacizumab in people with advanced, hard-to-treat liver cancer. It aims to see whether this combination can shrink tumors and improve outcomes after standard treatments don’t work or aren’t an option.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.